文献速递关节外科创伤骨科

富血小板血浆灌注联合髓芯减压改善早期股骨头缺血性坏死功能结局并延缓进展:一项4.5至6年前瞻性随机对照研究

Combining Platelet-Rich Plasma Instillation With Core Decompression Improves Functional Outcome and Delays Progression in Early-Stage Avascular Necrosis of Femoral Head: a 4.5- to 6-Year Prospective Randomized Comparative Study.
PubMed 文献 · J Arthroplasty · 2020-07-12

前瞻性随机双盲对照研究纳入40例(53髋)早期股骨头缺血性坏死患者,比较富血小板血浆联合髓芯减压(A组19例25髋)与单纯髓芯减压(B组21例28髋),平均随访约64个月,结果显示联合组在疼痛、功能、Harris髋关节评分及生存率方面均优于单纯减压组,并延缓2期病变进展。

要点

  • 富血小板血浆联合髓芯减压较单纯髓芯减压显著改善疼痛评分(P=.00)、功能评分(P=.02)和Harris髋关节评分(P=.00)。
  • 2期病变进展率A组24% vs B组43%,差异有统计学意义(P=.025);1期病变两组均无进展。
  • 股骨头塌陷、任何手术及全髋关节置换的生存率A组/B组分别为84%/68%(P=.00)、76%/57%(P=.02)、92%/78%(P=.01)。

核心结论

  • 在早期股骨头缺血性坏死中,髓芯减压后使用富血小板血浆较单纯髓芯减压可显著缓解疼痛、改善中期功能结局、延缓疾病进展,并提高无再次手术(全髋关节置换)及无股骨头塌陷的生存率。

研究设计与样本

  • 前瞻性随机双盲对照研究,连续纳入年龄和性别匹配的40例患者(53髋),通过计算机生成的算法表随机分为2组。
  • A组为富血小板血浆联合髓芯减压,共19例(25髋);B组为单纯髓芯减压,共21例(28髋)。
  • 术后评估Harris髋关节评分,并使用磁共振成像通过改良Kerboul角量化坏死面积。
  • A组平均随访64.3个月(范围54-72),B组平均随访63.7个月(范围56-72)。

主要发现

  • 末次随访时,富血小板血浆组与对照组在疼痛评分(P=.00)、功能评分(P=.02)和Harris髋关节评分(P=.00)方面差异有统计学意义。
  • 1期病变无进展;2期病变A组进展24%,B组进展43%,差异有统计学意义(P=.025)。
  • 股骨头塌陷生存率A组84% vs B组68%(P=.00),任何手术生存率A组76% vs B组57%(P=.02),全髋关节置换生存率A组92% vs B组78%(P=.01),差异均有统计学意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Avascular necrosis of femoral head is a debilitating disease frequently progressing to femoral head collapse and joint destruction. The efficacy of core decompression (CD) remains controversial. METHODS: About 40 consecutive age-matched and gender-matched patients (53 hips) were randomized into 2 groups by computer-generated algorithm table in a prospective randomized double-blinded comparative study. Group A (platelet-rich plasma [PRP] with CD) included 19 patients (25 hips), and group B (CD only) included 21 patients (28 hips). Postoperative Harris Hip Score and magnetic resonance imaging to quantify the necrotic area by using modified Kerboul angle were done and evaluated. Mean follow-up was 64.3 months (range, 54-72) and 63.7 months (range, 56-72) in groups A and B, respectively. RESULTS: There was statistically significant difference between PRP and control groups in pain score (P = .00), functional score (P = .02), and Harris Hip Score (P = .00) at final follow-up. There was no progression in stage 1 disease. Stage 2 disease showed 24% progression in group A and 43% progression in group B. The difference was statistically significant (P = .025). Survivorship from femoral head collapse, any procedure, and total hip arthroplasty was 84%/68% (P = .00), 76%/57% (P = .02), and 92%/78% (P = .01) in 2 groups, which was statistically significant. CONCLUSION: PRP use after CD provides significant pain relief, better midterm functional outcome, retards the progression, and enhances the survivorship free from reoperation for hip arthroplasty and femoral head collapse in early stages of avascular necrosis of hip than CD alone.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Aggarwal AK, Poornalingam K, Jain A, et al. Combining Platelet-Rich Plasma Instillation With Core Decompression Improves Functional Outcome and Delays Progression in Early-Stage Avascular Necrosis of Femoral Head: a 4.5- to 6-Year Prospective Randomized Comparative Study. J Arthroplasty. 2020. PMID: 32741710. doi:10.1016/j.arth.2020.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。